Table 6. Rare EGFR and KRAS mutations and tumor response to EGFR TKI.
Mutations | N | Response | Response | Published response to |
to chemotherapy | to EGFR TKI | EGFR TKI | ||
EGFR mutations | ||||
p.K708N | 1 | PD | PD (E) | [47]PR with |
gefitinib with | ||||
p.K708M | ||||
p.V769M | 1 | PR | PD (E) | [33], [48]; |
No treatment | ||||
information | ||||
p. D770GY | 1 | PD | PR (E) | [36], [37] |
with a secondary | No treatment | |||
p.G719C mutation | information | |||
p.D770GY; | 1 | PR | PD (G) | [36], [37] |
without secondary | No treatment | |||
mutation | information | |||
p.L833F | 1 | PR | PD (G) | ND |
(dual KRAS mutation) | ||||
p.A840T | 2 | PR/PR | PD (E)/– | ND |
KRAS mutations | ||||
p.G13Y | 1 | PD | – | ND |
p.V14L | 1 | PR | – | ND |
PR is partial response, PD is progressive disease, – = no EGFR TKI treatment; (E) = erlotinib, (G) = gefitinib, ND = Not described.